FindTrial
Sign In

A prospective study for Sentinel Lymph Node Mapping in endometrial cancer

The efficacy of SLN mapping technologies in predicting retroperitoneum lymph node metattasis in endometrial cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020483
Enrollment
Unknown
Registered
2019-01-02
Start date
2016-06-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometrial cancer

Interventions

Gold Standard:systemmatic lymphadenectomy
Index test:cervical injection of indocyanine green (ICG) sentinel lymph node (SLN) mapping

Sponsors

Shanghai First Maternity and Infant Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Endometrial cancer patient older than 18 years of age, with a presumed preoperative stage I or II disease defined as normal preoperative computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen/pelvis and normal pulmonary imaging (Chest X-ray or CT scan of the chest).

Exclusion criteria

Exclusion criteria: Patients had evidence of extra-uterine disease, had undergone previous treatment for their endometrial cancer, or had contraindications for receiving the ICG tracer, including a history of hepatic impairment or an iodine allergy. All enrolled patients gave written informed consent.

Design outcomes

Primary

MeasureTime frame
sensitivity;negative predictive value;false negative rate;SPE;ACC;—

Countries

China

Contacts

Public ContactXiaoping Wan

Department of Gynecology, Shanghai First Maternity and Infant Hospital

wanxiaoping@tongji.edu.cn+86 021 20261000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026